Compare AM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AM | IMVT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2017 | 2019 |
| Metric | AM | IMVT |
|---|---|---|
| Price | $19.79 | $29.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 17 |
| Target Price | $24.00 | ★ $48.88 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.30% | N/A |
| EPS Growth | ★ 3.61 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $1,188,426,000.00 | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | $16.00 | ★ N/A |
| Revenue Growth | ★ 7.43 | N/A |
| 52 Week Low | $17.12 | $21.43 |
| 52 Week High | $23.84 | $45.42 |
| Indicator | AM | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 40.73 |
| Support Level | $20.86 | $26.01 |
| Resistance Level | $21.84 | $29.83 |
| Average True Range (ATR) | 0.61 | 1.07 |
| MACD | 0.08 | 0.40 |
| Stochastic Oscillator | 57.58 | 71.35 |
Antero Midstream Corp is a midstream company that owns, operates, and develops midstream energy assets that service Antero Resources' production and completion activity in the Appalachian Basin, located in West Virginia and Ohio. The company has two operating segments: the Gathering and Processing segment, which includes a network of gathering pipelines and compressor stations that collect and process production from Antero Resources wells in West Virginia and Ohio, and the Water Handling segment, which includes two independent systems that deliver water from sources including the Ohio River, local reservoirs, and several regional waterways. The company derives a majority of its revenue from the Gathering and Processing segment.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.